Chemically synthesized sugar-cholestanols possess a preferential anticancer activity involving promising therapeutic potential against human esophageal cancer

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1358-1367

  Faried, Ahmad ^a,b   Faried, Leri S ^a   Nakagawa, Takashi ^c   Yamauchi, Takahito ^c   Kitani, Mami ^c   Sasabe, Hiroyuki ^c   Nishimura, Toyo ^c   Usman, Nurhayat ^b   Kato, Hiroyuki ^a   Asao, Takayuki ^a   Kuwano, Hiroyuki ^a   Yazawa, Shin ^a,c,d  

^a GUNMA UNIVERSITY   (Japan)

^b PADJADJARAN UNIVERSITY   (Indonesia)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA,5ALPHA CHOLESTANYL 2 ACETAMIDO 2 DEOXY BETA DEXTRO GLUCOPYRANOSIDE; 3BETA,5ALPHA CHOLESTANYL 3 O 2 ACETAMIDO 2 DEOXY BETA DEXTRO GLUCOPYRANOSIDE; 3BETA,5ALPHA CHOLESTANYL BETA DEXTRO GALACTOPYRANOSIDE; ANTINEOPLASTIC AGENT; CHOLESTANOL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SYNTHESIS; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CASPASES; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CHOLESTANOLS; ENZYME ACTIVATION; ESOPHAGEAL NEOPLASMS; GROWTH INHIBITORS; HUMANS; OLIGOSACCHARIDES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547760390     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00563.x     Document Type: Article

References (50)

1. Forastiere AA. Treatment of locoregional esophageal cancer. Semin Oncol 1992; 19 (Suppl 11): 57-63.
2. Baba M, Aikou T, Yoshinaka H et al. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994; 219: 310-16.
3. Le Prise E, Etienne PL, Meunier B et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73: 1779-84.
4. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.
5. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-13.
6. Carey RW, Hilgenberg AD, Wilkins EW Jr. et al. Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. Cancer Invest 1993; 11: 99-105.
7. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
8. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
9. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-16.
10. Baliga B, Kumar S. Apaf-1/cytochrome c apoptosome: An essential initiator of caspase activation or just a sideshow? Cell Death Differ 2003; 10: 16-18.
11. Riboni L, Viani P, Bassi R, Prinetti A, Tettamanti G. The role of sphingolipids in the process of signal transduction. Prog Lipid Res 1997; 36: 153-95.
12. Hakomori S. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J 2000; 17: 143-51.
13. Paris R, Morales A, Coll O, Sanchez-Reyes A, Garcia-Ruiz C, Fernandez-Checa JC. Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy. J Biol Chem 2002; 277: 49 870-6.
14. Morales A, Colell A, Mari M, Garcia-Ruiz C, Fernandez-Checa JC. Glycosphingolipids and mitochondria: Role in apoptosis and disease. Glycoconj J 2004; 20: 579-88.
15. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clement M. ABH and Lewis histo-blood group antigens in cancer. APMIS 2001; 109: 9-31.
16. Hakomori S. Cancer-associated glycosphingolipid antigens: Their structure, organization and function. Acta Anat (Basel) 1998; 161: 79-90.
17. Scorrano L, Petronilli V, Di Lisa F, Bernardi P. Commitment to apoptosis by GD3 ganglioside depends on opening of the mitochondrial permeability transition pore. J Biol Chem 1999; 274: 22 581-5.
18. Kristal BS, Brown AM. Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition. J Biol Chem 1999; 274: 23 169-75.
19. Garcia-Ruiz C, Colell A, Morales A, Calvo M, Enrich C, Fernandez-Checa JC. Trafficking of ganglioside GD3 to mitochondria by tumor necrosis factor-alpha. J Biol Chem 2002; 277: 36 443-8.
20. Akamatsu S, Yazawa S, Zenita K, Matsumoto H, Tachikawa T, Kannagi R. Elevation of an alpha (1,3) fucosyltransferase activity correlated with apoptosis in the human colon adenocarcinoma cell line, HT-29. Glycoconj J 1996; 13: 1021-9.
21. Yazawa S, Nishimura T, Ide M et al. Tumor-related expression of alpha1,2fucosylated antigens on colorectal carcinoma cells and its suppression by cell-mediated priming using sugar acceptors for alpha1,2fucosyltransferase. Glycobiology 2002; 12: 545-53.
22. Hashimoto S, Tsuboi K, Asao T et al. Anti-tumor effect of chemically synthesized novel glycoconjugates. Glycoconj J 2005; 22: 311.
23. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
24. Du JR, Jiang Y, Zhang YM, Fu H. Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003; 9: 1604-6.
25. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
26. Ludovini V, Sidoni A, Pistola L et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 2003; 81: 159-68.
27. Inoue K, Kamada M, Slaton J et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002; 8: 1863-70.
28. Kitadai Y, Haruma K, Tokutomi T et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998; 4: 2195-200.
29. Faried A, Kimura H, Faried LS et al. Expression of carbohydrate antigens in human esophageal squamous cell carcinoma. Ann Surg Oncol 2007; 14: 960-7.
30. Koochekpour S, Pilkington GJ. Vascular and perivascular GD3 expression in human glioma. Cancer Lett 1996; 104: 97-102.
31. Zeng G, Gao L, Birkle S, Yu SK. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res 2006; 60: 6670-6.
32. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993; 119: 441-9.
33. Sashiyama H, Shino Y, Sakao S et al. Alteration of integrin expression rates to malignant progression of human papillomavirus-immortalized esophageal keratinocytes. Cancer Lett 2002; 177: 21-8.
34. Goto J, Suzaki K, Nambara T. Synthesis of conjugated cholesterol and cholestanols. Chem Pharm Bull (Tokyo) 1979; 27: 1926-31.
35. Yazawa S, Nishimura T, Tanaka S et al. Preparation of cholestanol glycosides as anticancer agents. Chem Abstr 2000; 133: 74 264.
36. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol 2000; 10: 73-80.
37. Spiegel S, Milstien S. Sphingosine-1-phosphate: Signaling inside and out. FEBS Lett 2000; 476: 55-7.
38. Kolesnick R, Hannun YA. Ceramide and apoptosis. Trends Biochem Sci 1999; 24: 224-5.
39. Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta 2002; 1585: 153-62.
40. Radin NS. Killing tumors by ceramide-induced apoptosis: A critique of available drugs. Biochem J 2003; 371: 243-56.
41. Ma R, Koulov A, Moulton C et al. Apoptosis of human breast carcinoma cells in the presence of disialosyl gangliosides: II. Treatment of SKBR3 cells with GD3 and GD1b gangolisides. Glycoconj J 2004; 20: 319-30.
42. Brown JR, Fuster MM, Whisenant T, Esko JD. Expression patterns of alpha 2,3-sialyltransferases and alpha 1,3-fucosyltransferases determine the mode of sialyl Lewis X inhibition by disaccharide decoys. J Biol Chem 2003; 278: 23 352-9.
43. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression - The Warburg effect revisited. Glycoconj J 2004; 20: 353-64.
44. Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-88.
45. Kim R. Recent advances in understanding the cell death pathways activated by certain therapy. Cancer 2005; 103: 1551-60.
46. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-4.
47. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
48. Rak J, Kerbel RS. bFGF and tumor angiogenesis - back in the limelight? Nat Med 1997; 3: 1083-4.
49. Ueda M, Ueki K, Kumagai K et al. Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy. Cancer Res 1998; 58: 2343-6.
50. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-68.